Quarterly ResultAug 5, 2026, 04:24 PM
Tenaya Therapeutics Q2 Net Loss $43.4M; $21.8M Impairment Loss
AI Summary
Tenaya Therapeutics reported a net loss of $43.4 million for the second quarter of 2026, significantly impacted by a $21.8 million impairment loss and a $1.4 million loss on lease termination related to its Genetic Medicine Manufacturing Center. Despite these charges, the company recognized $1.1 million in collaboration revenue from a new agreement with Alnylam Pharmaceuticals, which also offers potential future milestone payments up to $1.1 billion. As of June 30, 2026, Tenaya held $78.1 million in cash and cash equivalents, with management projecting sufficient liquidity for at least the next twelve months.
Key Highlights
- Reported a net loss of $43.4 million for the three months ended June 30, 2026, compared to $23.3 million in Q2 2025.
- Incurred an impairment loss of $21.8 million related to the early termination of the GMMC Facility lease.
- Recognized a loss on lease termination of $1.4 million for the three months ended June 30, 2026.
- Collaboration revenue was $1.1 million for Q2 2026, stemming from the new Alnylam agreement.
- Cash and cash equivalents totaled $78.1 million as of June 30, 2026.
- Accumulated deficit reached $667.7 million as of June 30, 2026.
- Management believes existing cash will fund operations for at least the next twelve months.
- Alnylam collaboration includes potential future milestone payments of up to $1.1 billion.
Price Impact
More from TNYA